Peripheral neuropathy in prediabetes and the metabolic syndrome.
Amro Maher StinoAlbert G SmithPublished in: Journal of diabetes investigation (2017)
Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most common cause of neuropathy, accounting for 50% of cases. Over half of people with diabetes develop neuropathy, and diabetic peripheral neuropathy (DPN) is a major cause of reduced quality of life due to pain, sensory loss, gait instability, fall-related injury, and foot ulceration and amputation. Most patients with non-diabetic neuropathy have cryptogenic sensory peripheral neuropathy (CSPN). A growing body of literature links prediabetes, obesity and metabolic syndrome to the risk of both DPN and CSPN. This association might be particularly strong in type 2 diabetes patients. There are no effective medical treatments for CSPN or DPN, and aggressive glycemic control is an effective approach to neuropathy risk reduction only in type 1 diabetes. Several studies suggest lifestyle-based treatments that integrate dietary counseling with exercise might be a promising therapeutic approach to early DPN in type 2 diabetes and CSPN associated with prediabetes, obesity and metabolic syndrome.
Keyphrases
- type diabetes
- metabolic syndrome
- glycemic control
- insulin resistance
- blood glucose
- uric acid
- weight loss
- cardiovascular disease
- end stage renal disease
- cardiovascular risk factors
- newly diagnosed
- systematic review
- healthcare
- high fat diet induced
- multiple sclerosis
- ejection fraction
- chronic pain
- physical activity
- neuropathic pain
- peritoneal dialysis
- prognostic factors
- weight gain
- spinal cord
- spinal cord injury
- skeletal muscle
- lower limb
- wound healing
- case control
- human immunodeficiency virus
- antiretroviral therapy
- body mass index